nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—ESR1—hematologic cancer	0.312	1	CbGaD
Fulvestrant—CYP3A4—Bexarotene—hematologic cancer	0.0204	0.0829	CbGbCtD
Fulvestrant—CYP3A4—Lomustine—hematologic cancer	0.019	0.0771	CbGbCtD
Fulvestrant—CYP3A4—Busulfan—hematologic cancer	0.019	0.0771	CbGbCtD
Fulvestrant—ESR2—ovarian follicle—hematologic cancer	0.0178	0.25	CbGeAlD
Fulvestrant—CYP3A4—Thiotepa—hematologic cancer	0.0169	0.0687	CbGbCtD
Fulvestrant—CYP3A4—Methoxsalen—hematologic cancer	0.0131	0.0534	CbGbCtD
Fulvestrant—CYP3A4—Bortezomib—hematologic cancer	0.0125	0.0508	CbGbCtD
Fulvestrant—ESR1—ovarian follicle—hematologic cancer	0.0122	0.171	CbGeAlD
Fulvestrant—CYP3A4—Daunorubicin—hematologic cancer	0.012	0.0486	CbGbCtD
Fulvestrant—CYP3A4—Cytarabine—hematologic cancer	0.0106	0.0429	CbGbCtD
Fulvestrant—CYP3A4—Teniposide—hematologic cancer	0.0104	0.0422	CbGbCtD
Fulvestrant—CYP3A4—Ifosfamide—hematologic cancer	0.00959	0.039	CbGbCtD
Fulvestrant—CYP3A4—Imatinib—hematologic cancer	0.00916	0.0372	CbGbCtD
Fulvestrant—CYP3A4—Ruxolitinib—hematologic cancer	0.00863	0.0351	CbGbCtD
Fulvestrant—CYP3A4—Nilotinib—hematologic cancer	0.00833	0.0338	CbGbCtD
Fulvestrant—CYP3A4—Vinorelbine—hematologic cancer	0.00826	0.0335	CbGbCtD
Fulvestrant—CYP3A4—Triamcinolone—hematologic cancer	0.00755	0.0307	CbGbCtD
Fulvestrant—CYP3A4—Dasatinib—hematologic cancer	0.00736	0.0299	CbGbCtD
Fulvestrant—CYP3A4—Mitoxantrone—hematologic cancer	0.00727	0.0295	CbGbCtD
Fulvestrant—CYP3A4—Betamethasone—hematologic cancer	0.00648	0.0263	CbGbCtD
Fulvestrant—CYP3A4—Prednisolone—hematologic cancer	0.00639	0.026	CbGbCtD
Fulvestrant—CYP3A4—Prednisone—hematologic cancer	0.00604	0.0245	CbGbCtD
Fulvestrant—CYP3A4—Irinotecan—hematologic cancer	0.00572	0.0233	CbGbCtD
Fulvestrant—CYP3A4—Vinblastine—hematologic cancer	0.00509	0.0207	CbGbCtD
Fulvestrant—CYP3A4—Vincristine—hematologic cancer	0.005	0.0203	CbGbCtD
Fulvestrant—NR1H4—hematopoietic system—hematologic cancer	0.00467	0.0656	CbGeAlD
Fulvestrant—CYP3A4—Etoposide—hematologic cancer	0.00458	0.0186	CbGbCtD
Fulvestrant—CYP3A4—Dexamethasone—hematologic cancer	0.00377	0.0153	CbGbCtD
Fulvestrant—CYP3A4—Doxorubicin—hematologic cancer	0.00313	0.0127	CbGbCtD
Fulvestrant—EPHX2—blood—hematologic cancer	0.0027	0.038	CbGeAlD
Fulvestrant—EPHX2—lung—hematologic cancer	0.00237	0.0333	CbGeAlD
Fulvestrant—ESRRA—blood—hematologic cancer	0.00237	0.0333	CbGeAlD
Fulvestrant—ESRRA—bone marrow—hematologic cancer	0.00229	0.0322	CbGeAlD
Fulvestrant—EPHX2—testis—hematologic cancer	0.00224	0.0314	CbGeAlD
Fulvestrant—ESR2—hematopoietic system—hematologic cancer	0.00215	0.0302	CbGeAlD
Fulvestrant—ESRRA—lung—hematologic cancer	0.00208	0.0292	CbGeAlD
Fulvestrant—ESRRA—testis—hematologic cancer	0.00196	0.0275	CbGeAlD
Fulvestrant—NR1H4—lymph node—hematologic cancer	0.00186	0.0261	CbGeAlD
Fulvestrant—ESR2—gonad—hematologic cancer	0.00163	0.0229	CbGeAlD
Fulvestrant—EPHX2—lymph node—hematologic cancer	0.00162	0.0228	CbGeAlD
Fulvestrant—ESR1—hematopoietic system—hematologic cancer	0.00147	0.0207	CbGeAlD
Fulvestrant—ESR2—blood—hematologic cancer	0.00142	0.02	CbGeAlD
Fulvestrant—ESRRA—lymph node—hematologic cancer	0.00142	0.02	CbGeAlD
Fulvestrant—ESR2—lung—hematologic cancer	0.00125	0.0175	CbGeAlD
Fulvestrant—ESR2—testis—hematologic cancer	0.00118	0.0165	CbGeAlD
Fulvestrant—ESR1—gonad—hematologic cancer	0.00112	0.0157	CbGeAlD
Fulvestrant—ESR1—blood—hematologic cancer	0.000974	0.0137	CbGeAlD
Fulvestrant—ESR1—lung—hematologic cancer	0.000854	0.012	CbGeAlD
Fulvestrant—ESR2—lymph node—hematologic cancer	0.000853	0.012	CbGeAlD
Fulvestrant—CYP3A4—hematopoietic system—hematologic cancer	0.00082	0.0115	CbGeAlD
Fulvestrant—ESR1—testis—hematologic cancer	0.000806	0.0113	CbGeAlD
Fulvestrant—Estradiol—UGT1A1—hematologic cancer	0.000707	0.243	CrCbGaD
Fulvestrant—ESR1—lymph node—hematologic cancer	0.000584	0.0082	CbGeAlD
Fulvestrant—Estradiol—SLC22A1—hematologic cancer	0.000568	0.196	CrCbGaD
Fulvestrant—CYP3A4—blood—hematologic cancer	0.000543	0.00763	CbGeAlD
Fulvestrant—Estradiol—AR—hematologic cancer	0.000505	0.174	CrCbGaD
Fulvestrant—Estradiol—ABCG2—hematologic cancer	0.000397	0.137	CrCbGaD
Fulvestrant—Estradiol—ESR1—hematologic cancer	0.000389	0.134	CrCbGaD
Fulvestrant—Estradiol—ALB—hematologic cancer	0.000173	0.0596	CrCbGaD
Fulvestrant—Estradiol—ABCB1—hematologic cancer	0.000165	0.0569	CrCbGaD
Fulvestrant—Vomiting—Irinotecan—hematologic cancer	4.64e-05	0.000198	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—hematologic cancer	4.62e-05	0.000197	CcSEcCtD
Fulvestrant—Nausea—Alitretinoin—hematologic cancer	4.62e-05	0.000197	CcSEcCtD
Fulvestrant—Rash—Irinotecan—hematologic cancer	4.6e-05	0.000196	CcSEcCtD
Fulvestrant—Rash—Mitoxantrone—hematologic cancer	4.6e-05	0.000196	CcSEcCtD
Fulvestrant—Dermatitis—Mitoxantrone—hematologic cancer	4.59e-05	0.000196	CcSEcCtD
Fulvestrant—Dermatitis—Irinotecan—hematologic cancer	4.59e-05	0.000196	CcSEcCtD
Fulvestrant—Headache—Irinotecan—hematologic cancer	4.57e-05	0.000195	CcSEcCtD
Fulvestrant—Headache—Mitoxantrone—hematologic cancer	4.57e-05	0.000195	CcSEcCtD
Fulvestrant—Nausea—Ifosfamide—hematologic cancer	4.56e-05	0.000195	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.55e-05	0.000194	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.55e-05	0.000194	CcSEcCtD
Fulvestrant—Arthralgia—Prednisone—hematologic cancer	4.54e-05	0.000194	CcSEcCtD
Fulvestrant—Myalgia—Prednisone—hematologic cancer	4.54e-05	0.000194	CcSEcCtD
Fulvestrant—Diarrhoea—Cisplatin—hematologic cancer	4.53e-05	0.000193	CcSEcCtD
Fulvestrant—Anxiety—Prednisone—hematologic cancer	4.52e-05	0.000193	CcSEcCtD
Fulvestrant—Vomiting—Gemcitabine—hematologic cancer	4.52e-05	0.000193	CcSEcCtD
Fulvestrant—Insomnia—Dexamethasone—hematologic cancer	4.52e-05	0.000193	CcSEcCtD
Fulvestrant—Insomnia—Betamethasone—hematologic cancer	4.52e-05	0.000193	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.51e-05	0.000192	CcSEcCtD
Fulvestrant—Paraesthesia—Dexamethasone—hematologic cancer	4.48e-05	0.000191	CcSEcCtD
Fulvestrant—Paraesthesia—Betamethasone—hematologic cancer	4.48e-05	0.000191	CcSEcCtD
Fulvestrant—Rash—Gemcitabine—hematologic cancer	4.48e-05	0.000191	CcSEcCtD
Fulvestrant—Dermatitis—Gemcitabine—hematologic cancer	4.48e-05	0.000191	CcSEcCtD
Fulvestrant—Hypersensitivity—Etoposide—hematologic cancer	4.47e-05	0.000191	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—hematologic cancer	4.45e-05	0.00019	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—hematologic cancer	4.45e-05	0.00019	CcSEcCtD
Fulvestrant—Headache—Gemcitabine—hematologic cancer	4.45e-05	0.00019	CcSEcCtD
Fulvestrant—Nausea—Vincristine—hematologic cancer	4.45e-05	0.00019	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—hematologic cancer	4.43e-05	0.000189	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—hematologic cancer	4.43e-05	0.000189	CcSEcCtD
Fulvestrant—Hypersensitivity—Prednisolone—hematologic cancer	4.41e-05	0.000188	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—hematologic cancer	4.4e-05	0.000188	CcSEcCtD
Fulvestrant—Dyspepsia—Betamethasone—hematologic cancer	4.4e-05	0.000188	CcSEcCtD
Fulvestrant—Dyspepsia—Dexamethasone—hematologic cancer	4.4e-05	0.000188	CcSEcCtD
Fulvestrant—Urticaria—Triamcinolone—hematologic cancer	4.37e-05	0.000187	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—hematologic cancer	4.36e-05	0.000186	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—hematologic cancer	4.35e-05	0.000186	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—hematologic cancer	4.35e-05	0.000186	CcSEcCtD
Fulvestrant—Body temperature increased—Triamcinolone—hematologic cancer	4.35e-05	0.000186	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—hematologic cancer	4.34e-05	0.000185	CcSEcCtD
Fulvestrant—Decreased appetite—Betamethasone—hematologic cancer	4.34e-05	0.000185	CcSEcCtD
Fulvestrant—Decreased appetite—Dexamethasone—hematologic cancer	4.34e-05	0.000185	CcSEcCtD
Fulvestrant—Nausea—Mitoxantrone—hematologic cancer	4.33e-05	0.000185	CcSEcCtD
Fulvestrant—Nausea—Irinotecan—hematologic cancer	4.33e-05	0.000185	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—hematologic cancer	4.32e-05	0.000185	CcSEcCtD
Fulvestrant—Infection—Prednisone—hematologic cancer	4.32e-05	0.000184	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.31e-05	0.000184	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.31e-05	0.000184	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—hematologic cancer	4.31e-05	0.000184	CcSEcCtD
Fulvestrant—Fatigue—Dexamethasone—hematologic cancer	4.31e-05	0.000184	CcSEcCtD
Fulvestrant—Fatigue—Betamethasone—hematologic cancer	4.31e-05	0.000184	CcSEcCtD
Fulvestrant—Pruritus—Etoposide—hematologic cancer	4.29e-05	0.000183	CcSEcCtD
Fulvestrant—Pain—Betamethasone—hematologic cancer	4.27e-05	0.000182	CcSEcCtD
Fulvestrant—Pain—Dexamethasone—hematologic cancer	4.27e-05	0.000182	CcSEcCtD
Fulvestrant—Nervous system disorder—Prednisone—hematologic cancer	4.26e-05	0.000182	CcSEcCtD
Fulvestrant—Skin disorder—Prednisone—hematologic cancer	4.22e-05	0.00018	CcSEcCtD
Fulvestrant—Nausea—Gemcitabine—hematologic cancer	4.22e-05	0.00018	CcSEcCtD
Fulvestrant—Vomiting—Cisplatin—hematologic cancer	4.21e-05	0.00018	CcSEcCtD
Fulvestrant—Hyperhidrosis—Prednisone—hematologic cancer	4.2e-05	0.000179	CcSEcCtD
Fulvestrant—Rash—Cisplatin—hematologic cancer	4.18e-05	0.000178	CcSEcCtD
Fulvestrant—Dermatitis—Cisplatin—hematologic cancer	4.17e-05	0.000178	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—hematologic cancer	4.17e-05	0.000178	CcSEcCtD
Fulvestrant—Diarrhoea—Etoposide—hematologic cancer	4.15e-05	0.000177	CcSEcCtD
Fulvestrant—Anorexia—Prednisone—hematologic cancer	4.15e-05	0.000177	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—hematologic cancer	4.12e-05	0.000176	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.08e-05	0.000174	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Betamethasone—hematologic cancer	4.08e-05	0.000174	CcSEcCtD
Fulvestrant—Hypersensitivity—Triamcinolone—hematologic cancer	4.05e-05	0.000173	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—hematologic cancer	4.03e-05	0.000172	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—hematologic cancer	4.02e-05	0.000171	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—hematologic cancer	4.01e-05	0.000171	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—hematologic cancer	4e-05	0.000171	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—hematologic cancer	4e-05	0.000171	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—hematologic cancer	3.99e-05	0.00017	CcSEcCtD
Fulvestrant—Urticaria—Dexamethasone—hematologic cancer	3.97e-05	0.000169	CcSEcCtD
Fulvestrant—Urticaria—Betamethasone—hematologic cancer	3.97e-05	0.000169	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.96e-05	0.000169	CcSEcCtD
Fulvestrant—Dizziness—Prednisolone—hematologic cancer	3.96e-05	0.000169	CcSEcCtD
Fulvestrant—Asthenia—Triamcinolone—hematologic cancer	3.95e-05	0.000168	CcSEcCtD
Fulvestrant—Body temperature increased—Dexamethasone—hematologic cancer	3.95e-05	0.000168	CcSEcCtD
Fulvestrant—Abdominal pain—Betamethasone—hematologic cancer	3.95e-05	0.000168	CcSEcCtD
Fulvestrant—Body temperature increased—Betamethasone—hematologic cancer	3.95e-05	0.000168	CcSEcCtD
Fulvestrant—Abdominal pain—Dexamethasone—hematologic cancer	3.95e-05	0.000168	CcSEcCtD
Fulvestrant—Nausea—Cisplatin—hematologic cancer	3.93e-05	0.000168	CcSEcCtD
Fulvestrant—Insomnia—Prednisone—hematologic cancer	3.93e-05	0.000168	CcSEcCtD
Fulvestrant—Paraesthesia—Prednisone—hematologic cancer	3.9e-05	0.000167	CcSEcCtD
Fulvestrant—Pruritus—Triamcinolone—hematologic cancer	3.89e-05	0.000166	CcSEcCtD
Fulvestrant—Cough—Methotrexate—hematologic cancer	3.89e-05	0.000166	CcSEcCtD
Fulvestrant—Vomiting—Etoposide—hematologic cancer	3.86e-05	0.000165	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—hematologic cancer	3.86e-05	0.000165	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—hematologic cancer	3.85e-05	0.000164	CcSEcCtD
Fulvestrant—Dyspepsia—Prednisone—hematologic cancer	3.83e-05	0.000163	CcSEcCtD
Fulvestrant—Rash—Etoposide—hematologic cancer	3.83e-05	0.000163	CcSEcCtD
Fulvestrant—Dermatitis—Etoposide—hematologic cancer	3.82e-05	0.000163	CcSEcCtD
Fulvestrant—Headache—Etoposide—hematologic cancer	3.8e-05	0.000162	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—hematologic cancer	3.79e-05	0.000162	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—hematologic cancer	3.79e-05	0.000162	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—hematologic cancer	3.79e-05	0.000162	CcSEcCtD
Fulvestrant—Decreased appetite—Prednisone—hematologic cancer	3.78e-05	0.000161	CcSEcCtD
Fulvestrant—Rash—Prednisolone—hematologic cancer	3.77e-05	0.000161	CcSEcCtD
Fulvestrant—Dermatitis—Prednisolone—hematologic cancer	3.77e-05	0.000161	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.77e-05	0.000161	CcSEcCtD
Fulvestrant—Fatigue—Prednisone—hematologic cancer	3.75e-05	0.00016	CcSEcCtD
Fulvestrant—Headache—Prednisolone—hematologic cancer	3.75e-05	0.00016	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—hematologic cancer	3.74e-05	0.00016	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—hematologic cancer	3.73e-05	0.000159	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—hematologic cancer	3.73e-05	0.000159	CcSEcCtD
Fulvestrant—Constipation—Prednisone—hematologic cancer	3.72e-05	0.000159	CcSEcCtD
Fulvestrant—Dizziness—Triamcinolone—hematologic cancer	3.64e-05	0.000155	CcSEcCtD
Fulvestrant—Cough—Epirubicin—hematologic cancer	3.64e-05	0.000155	CcSEcCtD
Fulvestrant—Infection—Methotrexate—hematologic cancer	3.61e-05	0.000154	CcSEcCtD
Fulvestrant—Nausea—Etoposide—hematologic cancer	3.6e-05	0.000154	CcSEcCtD
Fulvestrant—Asthenia—Dexamethasone—hematologic cancer	3.58e-05	0.000153	CcSEcCtD
Fulvestrant—Asthenia—Betamethasone—hematologic cancer	3.58e-05	0.000153	CcSEcCtD
Fulvestrant—Nervous system disorder—Methotrexate—hematologic cancer	3.56e-05	0.000152	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—hematologic cancer	3.56e-05	0.000152	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Prednisone—hematologic cancer	3.56e-05	0.000152	CcSEcCtD
Fulvestrant—Nausea—Prednisolone—hematologic cancer	3.55e-05	0.000152	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—hematologic cancer	3.55e-05	0.000151	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—hematologic cancer	3.55e-05	0.000151	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—hematologic cancer	3.55e-05	0.000151	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—hematologic cancer	3.54e-05	0.000151	CcSEcCtD
Fulvestrant—Pruritus—Dexamethasone—hematologic cancer	3.53e-05	0.000151	CcSEcCtD
Fulvestrant—Pruritus—Betamethasone—hematologic cancer	3.53e-05	0.000151	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—hematologic cancer	3.53e-05	0.000151	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.52e-05	0.00015	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—hematologic cancer	3.51e-05	0.00015	CcSEcCtD
Fulvestrant—Vomiting—Triamcinolone—hematologic cancer	3.5e-05	0.000149	CcSEcCtD
Fulvestrant—Rash—Triamcinolone—hematologic cancer	3.47e-05	0.000148	CcSEcCtD
Fulvestrant—Dermatitis—Triamcinolone—hematologic cancer	3.47e-05	0.000148	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—hematologic cancer	3.46e-05	0.000148	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—hematologic cancer	3.46e-05	0.000148	CcSEcCtD
Fulvestrant—Urticaria—Prednisone—hematologic cancer	3.45e-05	0.000147	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—hematologic cancer	3.45e-05	0.000147	CcSEcCtD
Fulvestrant—Headache—Triamcinolone—hematologic cancer	3.45e-05	0.000147	CcSEcCtD
Fulvestrant—Abdominal pain—Prednisone—hematologic cancer	3.44e-05	0.000147	CcSEcCtD
Fulvestrant—Body temperature increased—Prednisone—hematologic cancer	3.44e-05	0.000147	CcSEcCtD
Fulvestrant—Diarrhoea—Dexamethasone—hematologic cancer	3.42e-05	0.000146	CcSEcCtD
Fulvestrant—Diarrhoea—Betamethasone—hematologic cancer	3.42e-05	0.000146	CcSEcCtD
Fulvestrant—Infection—Epirubicin—hematologic cancer	3.38e-05	0.000144	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—hematologic cancer	3.36e-05	0.000144	CcSEcCtD
Fulvestrant—Nervous system disorder—Epirubicin—hematologic cancer	3.34e-05	0.000142	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.31e-05	0.000141	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—hematologic cancer	3.3e-05	0.000141	CcSEcCtD
Fulvestrant—Dizziness—Betamethasone—hematologic cancer	3.3e-05	0.000141	CcSEcCtD
Fulvestrant—Dizziness—Dexamethasone—hematologic cancer	3.3e-05	0.000141	CcSEcCtD
Fulvestrant—Hyperhidrosis—Epirubicin—hematologic cancer	3.29e-05	0.00014	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—hematologic cancer	3.29e-05	0.00014	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—hematologic cancer	3.28e-05	0.00014	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—hematologic cancer	3.28e-05	0.00014	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—hematologic cancer	3.28e-05	0.00014	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—hematologic cancer	3.27e-05	0.00014	CcSEcCtD
Fulvestrant—Nausea—Triamcinolone—hematologic cancer	3.27e-05	0.000139	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—hematologic cancer	3.26e-05	0.000139	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.26e-05	0.000139	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—hematologic cancer	3.24e-05	0.000138	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—hematologic cancer	3.24e-05	0.000138	CcSEcCtD
Fulvestrant—Hypersensitivity—Prednisone—hematologic cancer	3.2e-05	0.000137	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—hematologic cancer	3.2e-05	0.000137	CcSEcCtD
Fulvestrant—Vomiting—Betamethasone—hematologic cancer	3.17e-05	0.000135	CcSEcCtD
Fulvestrant—Vomiting—Dexamethasone—hematologic cancer	3.17e-05	0.000135	CcSEcCtD
Fulvestrant—Decreased appetite—Methotrexate—hematologic cancer	3.16e-05	0.000135	CcSEcCtD
Fulvestrant—Rash—Betamethasone—hematologic cancer	3.15e-05	0.000134	CcSEcCtD
Fulvestrant—Rash—Dexamethasone—hematologic cancer	3.15e-05	0.000134	CcSEcCtD
Fulvestrant—Dermatitis—Dexamethasone—hematologic cancer	3.15e-05	0.000134	CcSEcCtD
Fulvestrant—Dermatitis—Betamethasone—hematologic cancer	3.15e-05	0.000134	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.14e-05	0.000134	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—hematologic cancer	3.13e-05	0.000134	CcSEcCtD
Fulvestrant—Headache—Betamethasone—hematologic cancer	3.13e-05	0.000133	CcSEcCtD
Fulvestrant—Headache—Dexamethasone—hematologic cancer	3.13e-05	0.000133	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—hematologic cancer	3.13e-05	0.000133	CcSEcCtD
Fulvestrant—Asthenia—Prednisone—hematologic cancer	3.12e-05	0.000133	CcSEcCtD
Fulvestrant—Pain—Methotrexate—hematologic cancer	3.11e-05	0.000133	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.1e-05	0.000132	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—hematologic cancer	3.09e-05	0.000132	CcSEcCtD
Fulvestrant—Pruritus—Prednisone—hematologic cancer	3.08e-05	0.000131	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—hematologic cancer	3.08e-05	0.000131	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—hematologic cancer	3.06e-05	0.00013	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—hematologic cancer	3.05e-05	0.00013	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—hematologic cancer	3.04e-05	0.00013	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—hematologic cancer	3.03e-05	0.000129	CcSEcCtD
Fulvestrant—Anorexia—Doxorubicin—hematologic cancer	3e-05	0.000128	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—hematologic cancer	2.99e-05	0.000128	CcSEcCtD
Fulvestrant—Diarrhoea—Prednisone—hematologic cancer	2.98e-05	0.000127	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—hematologic cancer	2.97e-05	0.000127	CcSEcCtD
Fulvestrant—Nausea—Dexamethasone—hematologic cancer	2.97e-05	0.000127	CcSEcCtD
Fulvestrant—Nausea—Betamethasone—hematologic cancer	2.97e-05	0.000127	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—hematologic cancer	2.96e-05	0.000126	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.94e-05	0.000125	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—hematologic cancer	2.93e-05	0.000125	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—hematologic cancer	2.91e-05	0.000124	CcSEcCtD
Fulvestrant—Pain—Epirubicin—hematologic cancer	2.91e-05	0.000124	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—hematologic cancer	2.89e-05	0.000123	CcSEcCtD
Fulvestrant—Dizziness—Prednisone—hematologic cancer	2.88e-05	0.000123	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—hematologic cancer	2.87e-05	0.000123	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—hematologic cancer	2.87e-05	0.000123	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.87e-05	0.000122	CcSEcCtD
Fulvestrant—Insomnia—Doxorubicin—hematologic cancer	2.85e-05	0.000121	CcSEcCtD
Fulvestrant—Paraesthesia—Doxorubicin—hematologic cancer	2.83e-05	0.000121	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—hematologic cancer	2.81e-05	0.00012	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Epirubicin—hematologic cancer	2.78e-05	0.000119	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—hematologic cancer	2.77e-05	0.000118	CcSEcCtD
Fulvestrant—Vomiting—Prednisone—hematologic cancer	2.76e-05	0.000118	CcSEcCtD
Fulvestrant—Rash—Prednisone—hematologic cancer	2.74e-05	0.000117	CcSEcCtD
Fulvestrant—Dermatitis—Prednisone—hematologic cancer	2.74e-05	0.000117	CcSEcCtD
Fulvestrant—Decreased appetite—Doxorubicin—hematologic cancer	2.74e-05	0.000117	CcSEcCtD
Fulvestrant—Headache—Prednisone—hematologic cancer	2.72e-05	0.000116	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.72e-05	0.000116	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—hematologic cancer	2.71e-05	0.000116	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—hematologic cancer	2.7e-05	0.000115	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Fulvestrant—Hypersensitivity—Methotrexate—hematologic cancer	2.68e-05	0.000114	CcSEcCtD
Fulvestrant—Asthenia—Methotrexate—hematologic cancer	2.61e-05	0.000111	CcSEcCtD
Fulvestrant—Nausea—Prednisone—hematologic cancer	2.58e-05	0.00011	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.57e-05	0.00011	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—hematologic cancer	2.57e-05	0.00011	CcSEcCtD
Fulvestrant—Hypersensitivity—Epirubicin—hematologic cancer	2.51e-05	0.000107	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—hematologic cancer	2.5e-05	0.000107	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—hematologic cancer	2.44e-05	0.000104	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—hematologic cancer	2.41e-05	0.000103	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—hematologic cancer	2.4e-05	0.000103	CcSEcCtD
Fulvestrant—Diarrhoea—Epirubicin—hematologic cancer	2.33e-05	9.93e-05	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—hematologic cancer	2.32e-05	9.89e-05	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—hematologic cancer	2.31e-05	9.86e-05	CcSEcCtD
Fulvestrant—Rash—Methotrexate—hematologic cancer	2.29e-05	9.78e-05	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—hematologic cancer	2.29e-05	9.77e-05	CcSEcCtD
Fulvestrant—Headache—Methotrexate—hematologic cancer	2.28e-05	9.71e-05	CcSEcCtD
Fulvestrant—Asthenia—Doxorubicin—hematologic cancer	2.26e-05	9.63e-05	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—hematologic cancer	2.25e-05	9.6e-05	CcSEcCtD
Fulvestrant—Pruritus—Doxorubicin—hematologic cancer	2.23e-05	9.5e-05	CcSEcCtD
Fulvestrant—Vomiting—Epirubicin—hematologic cancer	2.16e-05	9.23e-05	CcSEcCtD
Fulvestrant—Nausea—Methotrexate—hematologic cancer	2.16e-05	9.21e-05	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—hematologic cancer	2.15e-05	9.19e-05	CcSEcCtD
Fulvestrant—Rash—Epirubicin—hematologic cancer	2.14e-05	9.15e-05	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—hematologic cancer	2.14e-05	9.14e-05	CcSEcCtD
Fulvestrant—Headache—Epirubicin—hematologic cancer	2.13e-05	9.09e-05	CcSEcCtD
Fulvestrant—Dizziness—Doxorubicin—hematologic cancer	2.08e-05	8.88e-05	CcSEcCtD
Fulvestrant—Nausea—Epirubicin—hematologic cancer	2.02e-05	8.62e-05	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—hematologic cancer	2e-05	8.54e-05	CcSEcCtD
Fulvestrant—Rash—Doxorubicin—hematologic cancer	1.98e-05	8.47e-05	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—hematologic cancer	1.98e-05	8.46e-05	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—hematologic cancer	1.97e-05	8.41e-05	CcSEcCtD
Fulvestrant—Nausea—Doxorubicin—hematologic cancer	1.87e-05	7.98e-05	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—hematologic cancer	1.62e-05	0.000122	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NUP214—hematologic cancer	1.62e-05	0.000121	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—hematologic cancer	1.61e-05	0.000121	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CREBBP—hematologic cancer	1.6e-05	0.00012	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL17—hematologic cancer	1.57e-05	0.000117	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AGRN—hematologic cancer	1.57e-05	0.000117	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	1.55e-05	0.000116	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—hematologic cancer	1.54e-05	0.000116	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCR5—hematologic cancer	1.54e-05	0.000115	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.53e-05	0.000114	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	1.52e-05	0.000114	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MAPK14—hematologic cancer	1.52e-05	0.000114	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CD—hematologic cancer	1.52e-05	0.000114	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.51e-05	0.000113	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—NOTCH1—hematologic cancer	1.51e-05	0.000113	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LEF1—hematologic cancer	1.51e-05	0.000113	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—CREBBP—hematologic cancer	1.5e-05	0.000113	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—hematologic cancer	1.5e-05	0.000112	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ALB—hematologic cancer	1.5e-05	0.000112	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ESR1—hematologic cancer	1.49e-05	0.000112	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EIF4EBP1—hematologic cancer	1.49e-05	0.000111	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—HSPB1—hematologic cancer	1.49e-05	0.000111	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GNA13—hematologic cancer	1.48e-05	0.000111	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—hematologic cancer	1.48e-05	0.000111	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TIAM1—hematologic cancer	1.46e-05	0.000109	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—NOTCH1—hematologic cancer	1.44e-05	0.000108	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3R1—hematologic cancer	1.43e-05	0.000107	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTEN—hematologic cancer	1.43e-05	0.000107	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—SMC1A—hematologic cancer	1.42e-05	0.000107	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	1.42e-05	0.000106	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JAK3—hematologic cancer	1.42e-05	0.000106	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	1.4e-05	0.000105	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—H3F3A—hematologic cancer	1.4e-05	0.000105	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.39e-05	0.000104	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—CREBBP—hematologic cancer	1.37e-05	0.000103	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—hematologic cancer	1.37e-05	0.000103	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—hematologic cancer	1.36e-05	0.000102	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—EP300—hematologic cancer	1.36e-05	0.000102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCR7—hematologic cancer	1.36e-05	0.000102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL13—hematologic cancer	1.36e-05	0.000102	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.35e-05	0.000101	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NCOR2—hematologic cancer	1.34e-05	0.0001	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EZH2—hematologic cancer	1.34e-05	0.0001	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL3RA—hematologic cancer	1.32e-05	9.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CRKL—hematologic cancer	1.32e-05	9.91e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.32e-05	9.9e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CB—hematologic cancer	1.32e-05	9.9e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PARP1—hematologic cancer	1.31e-05	9.82e-05	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—CREBBP—hematologic cancer	1.31e-05	9.8e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RGS2—hematologic cancer	1.28e-05	9.56e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—HDAC2—hematologic cancer	1.26e-05	9.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TRIO—hematologic cancer	1.26e-05	9.45e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CMA1—hematologic cancer	1.26e-05	9.45e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TRH—hematologic cancer	1.26e-05	9.45e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CG—hematologic cancer	1.26e-05	9.44e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MAPK3—hematologic cancer	1.26e-05	9.4e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SPHK1—hematologic cancer	1.24e-05	9.25e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AGO2—hematologic cancer	1.24e-05	9.25e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HDAC9—hematologic cancer	1.22e-05	9.15e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LPAR1—hematologic cancer	1.22e-05	9.15e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—hematologic cancer	1.22e-05	9.14e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—H3F3B—hematologic cancer	1.21e-05	9.06e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GMPS—hematologic cancer	1.18e-05	8.87e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—FTCD—hematologic cancer	1.18e-05	8.87e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PHYH—hematologic cancer	1.18e-05	8.87e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CREBBP—hematologic cancer	1.17e-05	8.75e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTEN—hematologic cancer	1.14e-05	8.55e-05	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.14e-05	8.51e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDE4B—hematologic cancer	1.12e-05	8.42e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CNR2—hematologic cancer	1.12e-05	8.42e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGF19—hematologic cancer	1.12e-05	8.36e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CD—hematologic cancer	1.11e-05	8.3e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RAC2—hematologic cancer	1.11e-05	8.29e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—DKK1—hematologic cancer	1.1e-05	8.22e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AR—hematologic cancer	1.1e-05	8.21e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ALB—hematologic cancer	1.09e-05	8.19e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT5B—hematologic cancer	1.09e-05	8.16e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—EP300—hematologic cancer	1.09e-05	8.16e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.08e-05	8.12e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ADCY7—hematologic cancer	1.06e-05	7.92e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3R1—hematologic cancer	1.05e-05	7.84e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—XIAP—hematologic cancer	1.03e-05	7.7e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CDKN2B—hematologic cancer	1.01e-05	7.57e-05	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CA—hematologic cancer	1.01e-05	7.55e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SH2B3—hematologic cancer	1e-05	7.51e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMARCA4—hematologic cancer	1e-05	7.51e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GZMB—hematologic cancer	9.96e-06	7.46e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNA1—hematologic cancer	9.73e-06	7.29e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HSPB1—hematologic cancer	9.67e-06	7.24e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EIF4EBP1—hematologic cancer	9.67e-06	7.24e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL3—hematologic cancer	9.67e-06	7.24e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CB—hematologic cancer	9.66e-06	7.23e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NCOR1—hematologic cancer	9.59e-06	7.18e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SDC1—hematologic cancer	9.56e-06	7.16e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTHLH—hematologic cancer	9.56e-06	7.16e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—DCK—hematologic cancer	9.47e-06	7.09e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ASNS—hematologic cancer	9.47e-06	7.09e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—B3GAT1—hematologic cancer	9.47e-06	7.09e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTGER4—hematologic cancer	9.31e-06	6.97e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LCK—hematologic cancer	9.26e-06	6.94e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MAPK3—hematologic cancer	9.17e-06	6.87e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—H3F3A—hematologic cancer	9.08e-06	6.8e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HDC—hematologic cancer	8.98e-06	6.72e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—hematologic cancer	8.92e-06	6.68e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR3C1—hematologic cancer	8.87e-06	6.64e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PRKCZ—hematologic cancer	8.83e-06	6.61e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PARP1—hematologic cancer	8.52e-06	6.38e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—hematologic cancer	8.46e-06	6.34e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FBXW7—hematologic cancer	8.39e-06	6.28e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTEN—hematologic cancer	8.35e-06	6.25e-05	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—hematologic cancer	8.23e-06	6.17e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HDAC2—hematologic cancer	8.22e-06	6.16e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCR4—hematologic cancer	8.22e-06	6.16e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CDA—hematologic cancer	8.21e-06	6.15e-05	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—hematologic cancer	8.14e-06	6.09e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CA—hematologic cancer	8.06e-06	6.03e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CBL—hematologic cancer	8.02e-06	6e-05	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MAPK3—hematologic cancer	7.99e-06	5.98e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—EP300—hematologic cancer	7.96e-06	5.96e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL3—hematologic cancer	7.93e-06	5.94e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PC—hematologic cancer	7.91e-06	5.92e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTPN1—hematologic cancer	7.8e-06	5.84e-05	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—hematologic cancer	7.77e-06	5.82e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MAPK14—hematologic cancer	7.68e-06	5.75e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RASGRP1—hematologic cancer	7.67e-06	5.74e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HSP90AA1—hematologic cancer	7.65e-06	5.73e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SYK—hematologic cancer	7.65e-06	5.73e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GBA—hematologic cancer	7.64e-06	5.72e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC35B2—hematologic cancer	7.64e-06	5.72e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT1—hematologic cancer	7.37e-06	5.52e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NOTCH1—hematologic cancer	7.28e-06	5.45e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTAP—hematologic cancer	6.98e-06	5.23e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GRB2—hematologic cancer	6.9e-06	5.17e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFA—hematologic cancer	6.88e-06	5.15e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KITLG—hematologic cancer	6.78e-06	5.08e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT5A—hematologic cancer	6.63e-06	4.97e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—CREBBP—hematologic cancer	6.6e-06	4.94e-05	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—hematologic cancer	6.58e-06	4.93e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN2B—hematologic cancer	6.57e-06	4.92e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD86—hematologic cancer	6.36e-06	4.76e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HES1—hematologic cancer	6.27e-06	4.7e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NCOR1—hematologic cancer	6.23e-06	4.67e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—FHL2—hematologic cancer	6.22e-06	4.66e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—hematologic cancer	6.19e-06	4.63e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CSF2—hematologic cancer	6.16e-06	4.62e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGF1—hematologic cancer	6.16e-06	4.62e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AGRN—hematologic cancer	6.1e-06	4.57e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FOXO1—hematologic cancer	6.07e-06	4.55e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFRB—hematologic cancer	6.06e-06	4.54e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFRA—hematologic cancer	5.97e-06	4.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JAK1—hematologic cancer	5.95e-06	4.46e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PRKCG—hematologic cancer	5.95e-06	4.46e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CA—hematologic cancer	5.89e-06	4.41e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HMMR—hematologic cancer	5.79e-06	4.33e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—IDH2—hematologic cancer	5.79e-06	4.33e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2RA—hematologic cancer	5.56e-06	4.16e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—hematologic cancer	5.49e-06	4.11e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ARNTL—hematologic cancer	5.44e-06	4.07e-05	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—hematologic cancer	5.39e-06	4.03e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PDGFB—hematologic cancer	5.36e-06	4.02e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ACP5—hematologic cancer	5.29e-06	3.96e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA9—hematologic cancer	5.29e-06	3.96e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TSC2—hematologic cancer	5.24e-06	3.92e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.22e-06	3.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR3—hematologic cancer	5.04e-06	3.78e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK14—hematologic cancer	4.99e-06	3.74e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—IDH1—hematologic cancer	4.98e-06	3.73e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.92e-06	3.68e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TXN—hematologic cancer	4.92e-06	3.68e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.92e-06	3.68e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FN1—hematologic cancer	4.84e-06	3.62e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.81e-06	3.61e-05	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—hematologic cancer	4.81e-06	3.6e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BAD—hematologic cancer	4.78e-06	3.58e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NFKBIA—hematologic cancer	4.78e-06	3.58e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NOTCH1—hematologic cancer	4.73e-06	3.54e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD80—hematologic cancer	4.64e-06	3.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CG—hematologic cancer	4.63e-06	3.47e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KIT—hematologic cancer	4.63e-06	3.47e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—UGT1A1—hematologic cancer	4.63e-06	3.46e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTPN11—hematologic cancer	4.55e-06	3.41e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CRABP1—hematologic cancer	4.5e-06	3.37e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC22A1—hematologic cancer	4.5e-06	3.37e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CREB1—hematologic cancer	4.41e-06	3.3e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.39e-06	3.28e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BRAF—hematologic cancer	4.35e-06	3.26e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL2—hematologic cancer	4.31e-06	3.23e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6R—hematologic cancer	4.3e-06	3.22e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CREBBP—hematologic cancer	4.29e-06	3.21e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NUP98—hematologic cancer	4.25e-06	3.18e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.12e-06	3.09e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.12e-06	3.09e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAP2K1—hematologic cancer	4.1e-06	3.07e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NUP214—hematologic cancer	4.09e-06	3.07e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CD—hematologic cancer	4.07e-06	3.05e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MAPK3—hematologic cancer	4.03e-06	3.02e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.01e-06	3e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTR—hematologic cancer	4.01e-06	3e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO2—hematologic cancer	3.93e-06	2.95e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—hematologic cancer	3.92e-06	2.93e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGF2—hematologic cancer	3.9e-06	2.92e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3R1—hematologic cancer	3.84e-06	2.88e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.81e-06	2.86e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JAK2—hematologic cancer	3.73e-06	2.8e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SDC1—hematologic cancer	3.73e-06	2.79e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MDM2—hematologic cancer	3.65e-06	2.73e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MTOR—hematologic cancer	3.55e-06	2.66e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CB—hematologic cancer	3.55e-06	2.66e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1B—hematologic cancer	3.33e-06	2.49e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—hematologic cancer	3.26e-06	2.44e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—hematologic cancer	3.26e-06	2.44e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—hematologic cancer	3.18e-06	2.38e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NQO1—hematologic cancer	3.17e-06	2.37e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CD44—hematologic cancer	3.17e-06	2.37e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JUN—hematologic cancer	3.17e-06	2.37e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1A—hematologic cancer	3.07e-06	2.3e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTEN—hematologic cancer	3.06e-06	2.3e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYCS—hematologic cancer	3e-06	2.25e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK8—hematologic cancer	3e-06	2.25e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.98e-06	2.23e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EP300—hematologic cancer	2.92e-06	2.19e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SRC—hematologic cancer	2.84e-06	2.13e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—hematologic cancer	2.77e-06	2.07e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—hematologic cancer	2.74e-06	2.05e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—hematologic cancer	2.73e-06	2.05e-05	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—hematologic cancer	2.72e-06	2.03e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.64e-06	1.98e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK3—hematologic cancer	2.62e-06	1.96e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—hematologic cancer	2.55e-06	1.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—hematologic cancer	2.54e-06	1.9e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.5e-06	1.87e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.43e-06	1.82e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.43e-06	1.82e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—hematologic cancer	2.35e-06	1.76e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CA—hematologic cancer	2.16e-06	1.62e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.15e-06	1.61e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—hematologic cancer	2.09e-06	1.57e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—hematologic cancer	2e-06	1.5e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—hematologic cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.8e-06	1.35e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—hematologic cancer	1.77e-06	1.32e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.67e-06	1.25e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.59e-06	1.19e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ALB—hematologic cancer	1.57e-06	1.17e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.38e-06	1.04e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTEN—hematologic cancer	1.19e-06	8.95e-06	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—EP300—hematologic cancer	1.14e-06	8.53e-06	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.43e-07	6.31e-06	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—hematologic cancer	6.89e-07	5.16e-06	CbGpPWpGaD
